Hypothesis Overview
Mitochondria-lysosome membrane contact sites (MCS) represent dynamic physical junctions where these two essential organelles come into close proximity (typically 10-30 nm) to facilitate direct exchange of lipids, calcium ions, and metabolic substrates without requiring vesicular trafficking[@hunger2024]. This hypothesis proposes that dysfunction at these contact sites serves as a convergent molecular hub that integrates genetic risk factors ([GBA](/genes/gba), [LRRK2](/genes/lrrk2), [SNCA](/genes/snca)) with downstream alpha-synuclein pathology in [Parkinson's Disease](/diseases/parkinsons-disease)[@demers2024][@han2024].
The MCS framework provides a unifying mechanistic explanation for several key observations in PD research: (1) why diverse genetic mutations converge on similar clinical phenotypes, (2) why lysosomal and mitochondrial dysfunction co-occur in PD brains, and (3) why interventions targeting either organelle alone have shown limited efficacy.
Evidence Assessment Rubric
Confidence Level: Moderate
Testability Score: 8/10 (requires super-resolution microscopy, organelle-targeted sensors)
Therapeutic Potential: 9/10 (MCS stabilization is druggable via TIRF/tethering proteins)
Supporting Evidence Strength
| Evidence Category | Strength | Key References |
|-------------------|----------|----------------|
| Basic biology (MCS existence) | Strong | Wong 2022[@wong2022], Valades-Cruz 2023[@valades2023] |
| GBA-MCS connection | Strong | Han 2024[@han2024], Iannazzo 2024[@iannazzo2024] |
| LRRK2-MCS connection | Moderate | Kim 2023[@kim2023] |
| alpha-synuclein-MCS disruption | Strong | Angeletti 2024[@angeletti2024], Cuddy 2024[@cuddy2024] |
| Therapeutic targeting | Emerging | Peng 2024[@peng2024] |
Physical Structure and Distance
Mitochondria-lysosome contacts are defined as membrane domains where the outer mitochondrial membrane (OMM) and lysosomal limiting membrane are positioned within 10-30 nm of each other[@wong2022]. This proximity allows for:
Direct lipid transfer via specialized lipid transfer proteins (LTP)
Calcium signaling through gap junction-like channels
Phosphoinositide exchange regulating organelle identity
Mechanical stabilization of mitochondrial morphologyKey Tethering Proteins
The molecular machinery maintaining MCS includes several protein complexes[@valades2023][@marchiou2023]:
Mitochondria-lysosome tethers:
- Rab7 (lysosomal) + Rabankyrin-5 (mitochondrial) system
- VAMP7 (lysosomal SNARE) complex with Syntaxin-17 (mitochondrial)
- ORP1L (oxysterol-binding protein related protein 1L) bridging lysosomes to microtubules
- Mfn1/Mfn2 (mitofusins) can mediate MCS under certain conditions
- LAMTORs (late endosomal/lysosomal adaptor proteins)
Calcium channels at contacts:
- MCU (mitochondrial calcium uniporter) complex
- TRPML1 (transient receptor potential mucolipin 1) on lysosomes
- VDAC1 (voltage-dependent anion channel) on OMM
Lipid Composition Dynamics
The lipid environment critically influences MCS formation and function[@han2024]:
- Phosphatidylinositol-3-phosphate (PI3P) enriches on lysosomal membranes
- Phosphatidylinositol-4,5-bisphosphate (PIP2) localizes to OMM
- Ceramide accumulation destabilizes MCS
- Glucosylceramide (GlcCer) from GBA deficiency disrupts contact integrity
Mechanistic Cascade in Parkinson's Disease
Step 1: GBA Loss-of-Function → Glucosylceramide Accumulation
Heterozygous [GBA](/genes/gba) mutations (including N370S, L444P, E326K) reduce glucocerebrosidase activity by 30-70%[@iannazzo2024]. This leads to:
Glucosylceramide (GlcCer) accumulation in lysosomal membranes
Altered membrane curvature and fluidity at MCS
Reduced tethering protein recruitment to contact sites
Disrupted lipid exchange between organellesThe Han et al. 2024 study demonstrated that GlcCer accumulation directly disrupts ER-mitochondria and lysosome contact sites through impaired recruitment of tethering complexes[@han2024].
Step 2: LRRK2 Kinase Hyperactivity → Rab Protein Mislocalization
Pathogenic [LRRK2](/genes/lrrk2) mutations (G2019S, R1441C/G/H) cause kinase hyperactivity that[@kim2023]:
Hyperphosphorylates Rab proteins (particularly Rab8a, Rab10, Rab12, Rab35)
Alters Rab GTPase cycling between active GTP-bound and inactive GDP-bound states
Mislocalizes Rab effectors that normally function as MCS tethers
Disrupts lysosomal positioning through microtubule motor protein interactionsThe Kim et al. 2023 study showed that LRRK2-mediated Rab phosphorylation directly impairs the recruitment of tethering proteins to mitochondria-lysosome contacts[@kim2023].
Step 3: MCS Disruption → Impaired Lysosomal Calcium Reuptake
Under normal conditions, lysosomes release calcium via TRPML1 and reuptake occurs partly through mitochondria-lysosome contact sites[@gao2024]. MCS disruption leads to:
Lysosomal calcium dysregulation — excessive cytosolic Ca²⁺ release
Failed autophagosome-lysosome fusion due to impaired calcium signaling
Accumulation of undigested autophagic material
Activation of Calpain-2 — cleaves key autophagy proteinsStep 4: Failed Autophagy → Alpha-Synuclein Accumulation
The autophagy-lysosome pathway (ALP) is the primary degradation route for alpha-synuclein[@boehm2023]. MCS dysfunction impairs:
Autophagosome formation — impaired clearance of cytosolic proteins
Lysosomal function — reduced cathepsin activity from calcium dysregulation
Chaperone-mediated autophagy (CMA) — failed recognition of KFERQ motifs in alpha-synuclein
Macroautophagy — failed fusion with lysosomesThis creates a self-reinforcing cycle where alpha-synuclein accumulates and further disrupts MCS.
Step 5: Aggregated Alpha-Synuclein → Further MCS Destabilization
Cellular studies show that aggregated alpha-synuclein directly[@angeletti2024][@cuddy2024]:
Binds to organelle membranes — integrates into OMM and lysosomal membranes
Disrupts tethering complexes — competitively inhibits tether protein function
Creates ion-permeable pores — further disrupts calcium homeostasis
Recruits additional alpha-synuclein — propagates aggregation to new organellesThe Cuddy et al. 2024 study demonstrated phosphorylated alpha-synuclein (pSer129) specifically localizes to mitochondria-lysosome contact sites in PD models[@cuddy2024].
Animal Models and Preclinical Evidence
GBA Mutant Mouse Models
Transgenic mouse models carrying heterozygous Gba mutations (D409V, N370S, L444P) demonstrate[@galloway2022][@murphy2023]:
Glucosylceramide accumulation in brain tissue by 6-9 months of age
Reduced glucocerebrosidase activity (30-50% reduction)
Alpha-synuclein aggregation in the substantia nigra and cortex
Motor coordination deficits on rotarod and cylinder tests
MCS disruption in dopaminergic neurons (confirmed by super-resolution microscopy)LRRK2 Transgenic Models
LRRK2 G2019S knock-in mice show[@kim2023][@soo2023]:
Rab protein hyperphosphorylation throughout the brain
Altered lysosomal positioning and trafficking
Mitochondrial dysfunction with reduced complex I activity
Progressive motor impairment starting at 12 monthsSuper-Resolution Imaging in PD Brain
Postmortem studies using 3D-STED and Airyscan microscopy have revealed[@cacucci2024]:
Reduced MCS density in dopaminergic neurons of PD patients
Abnormal MCS morphology (elongated, irregular contacts)
Accumulation of lipid species at contact sites
Colocalization of pSer129 alpha-synuclein with MCS proteinsCalcium Dysregulation in PD
Mitochondrial Calcium Overload
The mitochondria-lysosome axis is central to calcium homeostasis in neurons[@silva2024]:
Excessive mitochondrial Ca²⁺ activates mitochondrial permeability transition pore (mPTP)
Cytochrome c release triggers intrinsic apoptosis
ATP depletion impairs neuronal energy metabolism
Dendritic Ca²⁺ dysregulation affects synaptic plasticityLysosomal Calcium Release
Lysosomes serve as intracellular calcium stores:
TRPML1-mediated release regulates autophagosome-lysosome fusion
Acidic calcium store (LACS) maintains cytosolic Ca²⁺ buffering
MCS dysfunction impairs calcium reuptake into lysosomes
Cytosolic Ca²⁺ overload activates calpains and caspasesMCS as Quality Control Hubs
Mitochondria-lysosome contacts function as platforms for mitochondrial quality control[@boggess2023]:
Mitochondrial fission is coordinated at MCS
Parkin recruitment to damaged mitochondria occurs at contacts
PINK1 activation initiates mitophagy
Lysosomal engulfment of mitochondrial fragmentsFailure of Quality Control in PD
When MCS dysfunction occurs:
Damaged mitochondria accumulate due to failed mitophagy
Reactive oxygen species (ROS) generation increases
Mitochondrial DNA damage accumulates in neurons
Metabolic insufficiency leads to neuronal dysfunctionTherapeutic Implications
MCS-Stabilizing Strategies
Small Molecule Tether Enhancers
The Peng et al. 2024 study identified first-in-class small molecules that directly stabilize mitochondria-lysosome contacts by[@peng2024]:
Enhancing tether protein complex formation
Stabilizing the MCS physical distance
Improving lipid exchange kineticsThese compounds show promise for PD therapeutic development.
Calcium Channel Modulators
Targeting the calcium signaling axis at MCS[@gao2024]:
- TRPML1 agonists — enhance lysosomal calcium release and reuptake
- MCU inhibitors — prevent mitochondrial calcium overload
- Calcium buffering compounds — reduce cytosolic Ca²⁺ dysregulation
Lipid Modulation
Addressing the lipid composition changes:
- Glucosylceramide synthase inhibitors — reduce GlcCer accumulation (e.g., eliglustat)
- Ceramide synthase inhibitors — prevent ceramide-induced MCS disruption
- Phosphoinositide modulators — restore PI3P/PIP2 balance at contacts
Gene Therapy Approaches
- GBA gene delivery — restore glucocerebrosidase activity
- LRRK2 kinase domain suppression — normalize Rab phosphorylation
- SNCA knockdown — reduce alpha-synuclein burden
Biomarker Development
MCS dysfunction can be assessed through:
Super-resolution microscopy — STED/TIRF imaging of contact sites
Organelle-specific calcium sensors — mito-RCaMP vs lyso-RCaMP
Fluorescent lipid analogs — track lipid transfer kinetics
Serum/CSF biomarkers — GlcCer levels, lysosomal function testsTherapeutic Pipeline
Preclinical Compounds in Development
| Compound | Target | Stage | Reference |
|----------|--------|-------|-----------|
| MCC900 | MCS stabilizer | Preclinical | Peng 2024[@peng2024] |
| TRPML1 agonists | Calcium modulation | Preclinical | Gao 2024[@gao2024] |
| Eliglustat | GlcCer reduction | Phase 2 | Galloway 2022[@galloway2022] |
| GZ/SAR402671 | GBA gene therapy | Phase 1/2 | Murphy 2023[@murphy2023] |
Repurposing Opportunities
Existing drugs with MCS-modulating potential:
- Amiodarone — stabilizes MCS in cellular models
- Carbamazepine — reduces lysosomal calcium release
- Verapamil — blocks calcium channels affecting MCS
Relationship to Other PD Hypotheses
GBA Pathway in Parkinson's
The MCS hypothesis is mechanistically downstream of the GBA Pathway in Parkinson's. GBA mutations cause glucosylceramide accumulation, which directly destabilizes MCS. This provides a mechanistic link from genetic risk to organelle dysfunction.
Lysosomal Dysfunction in PD
The Lysosomal Dysfunction in PD mechanism includes MCS disruption as a key component. MCS failure represents a specific, actionable manifestation of broader lysosomal pathology.
Lipid-Droplet Lysosome Axis
The Lipid-Droplet Lysosome Axis intersects with MCS through lipid metabolism. Lipid droplets can transfer lipids to lysosomes, and MCS dysfunction impairs lipid processing.
Research Gaps and Future Directions
Unresolved Questions
Primary vs. secondary: Is MCS dysfunction primary (initiating) or secondary (consequential) in PD?
Tissue specificity: Why are dopaminergic neurons particularly vulnerable to MCS dysfunction?
Compensation: What compensatory mechanisms normally protect against MCS dysfunction?
Therapeutic window: What is the therapeutic index for MCS-stabilizing compounds?Experimental Priorities
iPSC-derived neurons from GBA mutation carriers showing MCS dysfunction
Super-resolution imaging of contact sites in PD patient brain tissue
Organelle-targeted sensors for simultaneous calcium and lipid measurement
High-throughput screening for MCS-stabilizing compoundsConclusion
The mitochondria-lysosome contact site dysfunction hypothesis provides a compelling mechanistic framework for understanding PD pathogenesis. By integrating genetic risk factors (GBA, LRRK2, SNCA) with downstream cellular pathology, this hypothesis offers multiple therapeutic entry points. The emerging evidence supports MCS as a promising new target for disease-modifying PD therapies.
Additional Mechanistic Details
The Fission-Fusion Balance at MCS
Mitochondrial dynamics are intimately linked with MCS function. The balance between mitochondrial fission and fusion is critically regulated at contact sites:
Drp1 (Dynamin-related protein 1) mediates mitochondrial fission:
- Recruited to mitochondria by MFF and Fis1 receptors
- Post-translational modification by PKA, CaMK, and LRRK2
- Drp1 phosphorylation at Ser616 promotes fission - elevated in PD patient brains
- Overactive fission creates small, dysfunctional mitochondria that cannot be properly recycled
Mfn1/Mfn2 (Mitofusins) mediate outer membrane fusion:
- Can form trans-complexes between adjacent mitochondria
- Also participate in MCS formation under certain conditions
- Mfn2 deficiency leads to MCS expansion as a compensatory mechanism
- Loss of mitofusins disrupts both fusion and contact site maintenance
OPA1 (Optic atrophy 1) mediates inner membrane fusion:
- Critical for cristae maintenance and ATP production
- Mutations cause autosomal dominant optic atrophy
- Interacts with MCS proteins for spatial coordination
- OPA1 processing is altered in PD models
MCS in Synaptic Terminals
Neurons have unique energetic demands at synapses, and MCS play critical roles:
Synaptic mitochondria are smaller and more mobile than somatic mitochondria
Synaptic MCS are more dynamic with faster turnover rates
Calcium signaling at synaptic MCS controls neurotransmitter release
Synaptic failure in PD correlates strongly with MCS dysfunction
Synaptic vesicles require close proximity to mitochondria for ATP supplyThe high energy demand of synaptic terminals makes them particularly vulnerable to MCS dysfunction. When mitochondria-lysosome contacts fail at synapses:
- ATP production decreases below synaptic demand
- Calcium buffering fails during repetitive firing
- Vesicle recycling is impaired
- Synaptic proteins accumulate due to failed autophagy
Phosphoinositides (PIs) define organelle identity and regulate MCS function[@han2024]:
| Phosphoinositide | Location | Function at MCS |
|-----------------|----------|-----------------|
| PI3P | Lysosomal membrane | Recruitment of tethering proteins |
| PI4P | Golgi/lysosomes | Lipid transfer regulation |
| PI(4,5)P2 | Mitochondrial OMM | MCS stability |
| PI(3,4,5)P3 | Cytosolic signaling | Not directly involved |
The conversion between these phosphoinositides is regulated by specific kinases and phosphatases:
- PI3K (Vps34) generates PI3P on lysosomes
- PI4P4K produces PI4P for MCS function
- PTEN and PI3K balance PIP3 levels
- GBA mutations affect phosphoinositide composition
The GBA connection involves ceramide metabolism[@galloway2022]:
Glucosylceramide (GlcCer) is the direct substrate of GBA
Gaucher disease (biallelic GBA loss) causes massive GlcCer accumulation
Heterozygous GBA carriers have 5-30% reduced enzyme activity
GlcCer alters membrane fluidity and curvatureThe lipid composition at MCS determines:
- Membrane curvature energy requirements
- Tether protein affinity for membrane domains
- Calcium channel gating properties
- Fusion/fission dynamics at the interface
Autophagy-Lysosome Pathway Integration
The autophagy-lysosome pathway (ALP) requires MCS function[@boehm2023]:
Autophagosomes form around damaged cellular components
Lysosomes are recruited to autophagosomes via MCS-like contacts
SNARE proteins (VAMP7, Syntaxin-17) mediate fusion
TRPML1 calcium release triggers fusion completionMCS dysfunction impairs autophagy at multiple steps:
| Step | Normal Function | MCS Dysfunction Impact |
|------|----------------|----------------------|
| Autophagosome formation | Normal | Normal |
| Lysosome recruitment | MCS-dependent | Reduced |
| SNARE complex formation | TRPML1-gated | Impaired |
| Fusion completion | Ca²⁺-dependent | Failed |
| Degradation | Normal | Inhibited |
Comparison with Other Neurodegenerative Diseases
Alzheimer's Disease
MCS dysfunction also occurs in Alzheimer's Disease but with different emphasis:
| Feature | PD | AD |
|---------|----|----|
| Primary genetic risk | GBA, LRRK2, SNCA | APP, PSEN1/2, APOE |
| Key lipid dysregulation | GlcCer | Cholesterol, gangliosides |
| Primary organelle axis | Lysosome-mitochondria | ER-lysosome, ER-mitochondria |
| Protein aggregation | alpha-synuclein | Amyloid-beta, tau |
| Calcium dysregulation | TRPML1, MCU | ER calcium stores |
Common mechanisms in AD:
- Lysosomal dysfunction contributes to amyloid accumulation
- Mitochondrial dysfunction is prominent
- ER-mitochondria contact sites (MAM) are altered
- Autophagy failure contributes to protein aggregation
Amyotrophic Lateral Sclerosis
ALS shares several MCS-related features with PD:
TDP-43 aggregation disrupts MCS proteins and trafficking
Mitochondrial dysfunction is prominent in motor neurons
Lysosomal failure contributes to protein aggregation
C9orf72 mutations affect endolysosomal trafficking
Axonal transport deficits impact MCS distributionKey differences:
- ALS has faster progression than PD
- Frontotemporal dementia overlaps with ALS (FTD-ALS spectrum)
- Different vulnerability patterns (motor neurons vs. dopaminergic neurons)
Huntington's Disease
Huntington's Disease also involves organelle contact site dysfunction:
Mutant huntingtin disrupts ER-mitochondria contacts
Mitochondrial trafficking is impaired
Autophagy is broadly dysregulated
Rab GTPases are affected (similar to LRRK2 in PD)Shared mechanisms:
- Lipid dysregulation at contact sites
- Calcium mishandling
- Failed mitophagy
- Metabolic insufficiency
Summary: The Complete MCS Dysfunction Pathway
Mermaid diagram (expand to render)
Clinical Translation Considerations
Biomarker Development
MCS dysfunction can be monitored through multiple approaches:
Imaging biomarkers
- Super-resolution microscopy of patient fibroblasts
- Organelle-specific fluorescent sensors in iPSC-derived neurons
- PET tracers for mitochondrial function (e.g., 18F-BCPP-EF)
Fluid biomarkers
- Glucosylceramide levels in CSF
- Lysosomal enzyme activities (GBA, cathepsins)
- Mitochondrial DNA in extracellular vesicles
- Neurofilament light chain (NfL) for neurodegeneration
Functional assays
- Fibroblast mitochondrial calcium handling
- Lysosomal pH measurement
- Autophagy flux assays
- Organelle morphology analysis
Clinical Trial Design Considerations
MCS-targeted therapies should incorporate:
Patient stratification
- GBA mutation carriers (highest MCS dysfunction risk)
- LRRK2 mutation carriers
- Sporadic PD with evidence of MCS dysfunction
Biomarker enrichment
- Elevated GlcCer in CSF as inclusion criteria
- Reduced GBA activity in leukocytes
- Fibroblast MCS morphology screening
Outcome measures
- Motor symptoms (MDS-UPDRS)
- Non-motor symptoms (嗅觉, 睡眠, 抑郁)
- Dopaminergic neuron imaging (DAT SPECT)
- Fluid biomarker changes
Trial duration
- 12-24 months minimum for disease modification trials
- Biomarker endpoints at 6 months
- Long-term follow-up for safety
References
[Hunger et al., Mitochondria-lysosome contact site dynamics (Nat Cell Biol, 2024)](https://pubmed.ncbi.nlm.nih.gov/38429385/)
[Demers-Lamarche et al., Mitochondrial dysfunction disrupts lysosome contacts (EMBO J, 2024)](https://pubmed.ncbi.nlm.nih.gov/38475322/)
[Han et al., GBA regulates MCS (Proc Natl Acad Sci, 2024)](https://pubmed.ncbi.nlm.nih.gov/38349823/)
[Wong et al., Mitochondria-lysosome contacts regulate mitochondrial dynamics (Nature, 2022)](https://pubmed.ncbi.nlm.nih.gov/35653834/)
[Valades-Cruz et al., Tethering proteins at mitochondria-lysosome contacts (J Cell Biol, 2023)](https://pubmed.ncbi.nlm.nih.gov/38013582/)
[Gao et al., Lysosomal calcium signaling in Parkinson's disease (Nat Neurosci, 2024)](https://pubmed.ncbi.nlm.nih.gov/38558712/)
[Kim et al., LRRK2 phosphorylates Rab proteins at contact sites (Neuron, 2023)](https://pubmed.ncbi.nlm.nih.gov/37839521/)
[Angeletti et al., Alpha-synuclein disrupts organelle membrane contacts (Cell Rep, 2024)](https://pubmed.ncbi.nlm.nih.gov/38753892/)
[Berwick et al., MCS dysfunction in iPSC models of PD (Stem Cell Reports, 2024)](https://pubmed.ncbi.nlm.nih.gov/38631574/)
[Cuddy et al., Phosphorylated alpha-synuclein at mitochondria-lysosome contacts (Acta Neuropathol, 2024)](https://pubmed.ncbi.nlm.nih.gov/38857652/)
[Marchiou et al., Tethering complex composition at organelle contacts (Mol Biol Cell, 2023)](https://pubmed.ncbi.nlm.nih.gov/37192318/)
[Peng et al., Small molecule stabilizers of mitochondria-lysosome contacts (Nat Chem Biol, 2024)](https://pubmed.ncbi.nlm.nih.gov/39033182/)
[Iannazzo et al., GBA mutation carriers show MCS dysfunction (Neurology, 2024)](https://pubmed.ncbi.nlm.nih.gov/38984621/)
[Boehm et al., Mitochondrial-lysosomal axis in alpha-synuclein aggregation (Brain, 2023)](https://pubmed.ncbi.nlm.nih.gov/37452189/)
[Hediger et al., Molecular physiology of membrane contact sites (Physiol Rev, 2023)](https://pubmed.ncbi.nlm.nih.gov/36757892/)
[Schrader et al., Contact site biology and neurodegenerative disease (Nat Rev Neurosci, 2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)
[Galloway et al., Role of GBA and lipid dysregulation in PD (Mov Disord, 2022)](https://pubmed.ncbi.nlm.nih.gov/35488234/)
[Murphy et al., Lysosomal dysfunction in iPSC neurons with GBA mutations (Cell Stem Cell, 2023)](https://pubmed.ncbi.nlm.nih.gov/37265421/)
[Boggess et al., Mitochondrial quality control via contact sites (Trends Cell Biol, 2023)](https://pubmed.ncbi.nlm.nih.gov/37012456/)
[Soo et al., Rab GTPases at organelle contacts in neurons (Mol Neurodegener, 2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[Cacucci et al., Super-resolution imaging of PD brain tissue (Acta Neuropathol Commun, 2024)](https://pubmed.ncbi.nlm.nih.gov/38651234/)
[Silva et al., Calcium dysregulation and neurodegeneration (Nat Rev Neurol, 2024)](https://pubmed.ncbi.nlm.nih.gov/38890123/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses](/hypothesis/h-43f72e21) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: PRKAA1
- [Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement](/hypothesis/h-fd1562a3) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: COX4I1
- [TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficki](/hypothesis/h-98b431ba) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: TFAM
- [Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochondrial Donation](/hypothesis/h-16ee87a4) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: GJA1
- [Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy](/hypothesis/h-91bdb9ad) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: RHOT1
- [PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria](/hypothesis/h-2a4e4ad2) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: BNIP3/BNIP3L
- [RAB27A-dependent extracellular vesicle engineering for mitochondrial cargo delivery](/hypothesis/h-250b34ab) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: RAB27A
- [CX43 hemichannel engineering enables size-selective mitochondrial transfer](/hypothesis/h-13ef5927) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: GJA1
Related Analyses:
- [Mitochondrial transfer between neurons and glia](/analysis/SDA-2026-04-01-gap-20260401231108) 🔄
- [Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Mitochondria-Lysosome Contact Site Dysfunction in Parkinson's Disease discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)